IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding IN8BIO, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 22 | 21 | −1 |
| Shares | 2.33M | 2.48M | +147.6K (+6.3%) |
| Value | $3.59M | $2.58M | −$1.01M (−28.2%) |
New holders (3)
Institutions that held IN8BIO, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Texas Capital Bank Wealth Management Services Inc | 42,445 | $44.1K | 0.01% |
| UBS Group AG | 4,968 | $5.17K | 0.00% |
| JPMorgan Chase & Co | 18 | $19 | 0.00% |
Sold out (4)
Institutions that held IN8BIO, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Citadel Advisors LLC | 57,722 | $88.9K |
| Renaissance Technologies LLC | 21,700 | $33.0K |
| Two Sigma Investments, LP | 18,189 | $28.0K |
| Dimensional Fund Advisors LP | 17,583 | $27.1K |